Peptide-conjugated nanoparticles for targeted photodynamic therapy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Nanophotonics Année : 2021

Peptide-conjugated nanoparticles for targeted photodynamic therapy

Résumé

Cancer is the second leading cause of death worldwide after cardiovascular disease. Depending on the type and the location of the tumor, several cancer treatments are implemented. Among these, the three most conventional therapies are surgery, radiotherapy and chemotherapy. However, there are other therapeutic approaches such as photodynamic therapy (PDT). PDT relies on the combined action of light, a photoactivable molecule called photosensitizer (PS) and molecular oxygen. Most of the PSs used for clinical applications are not cancer-cell specific. One of the solutions to overcome this problem is the use of nanoparticles (NPs) to induce a passive targeting. It is also possible to graft a vector onto the NPs to specifically target membrane receptors overexpressed in the tumor cells or neovessels surrounding the tumor. In this review, we focus on the NPs loaded with PSs and coupled to peptides for targeted PDT. We described nanosystems that targeted Neuropilin-1 (NRP-1), α v β 3 integrins, nucleolin membrane receptor, epidermal growth factor (EGF) receptor, proteinglutamine-gamma-glutamyltransferase (TGM2), p32, transferrin, PD-1, and mitochondrial membrane. The use of a cell absorbing-peptide is also described.
Fichier principal
Vignette du fichier
10.1515_nanoph-2021-0275.pdf (10.04 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03350919 , version 1 (21-09-2021)

Identifiants

Citer

Batoul Dhaini, Bibigul Kenzhebayeva, Amina Ben-Mihoub, Mickaël Gries, Samir Acherar, et al.. Peptide-conjugated nanoparticles for targeted photodynamic therapy. Nanophotonics, 2021, Nanophotonics and immunotherapy for cancer, 10 (12), pp.3089-3134. ⟨10.1515/nanoph-2021-0275⟩. ⟨hal-03350919⟩
82 Consultations
34 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More